In May 2025, Montana passed legislation permitting clinics to offer treatments not approved by the U.S. Food and Drug Administration (FDA), marking a dramatic expansion of the state’s “Right to Try” laws. This bill allows licensed experimental clinics to recommend and sell drugs that have completed only Phase I trials—the earliest and smallest clinical studies designed primarily to evaluate safety, not efficacy. While this has sparked both excitement and concern, its implications ripple far beyond Montana’s borders (Hamzelou, 2025).

Why This Matters to GMDP Academy Learners and Leaders

For professionals trained through the GMDP Academy’s Certification in Medicines Development (CMD), the Montana law presents a real-world test case for discussions held in Modules 4, 5, and 7—especially concerning regulatory science, ethics, patient autonomy, and global innovation pathways.

Montana is not alone. Around the world, various jurisdictions offer frameworks for access to unapproved treatments:

  • United States (Federal): The federal Right to Try Act (2018) permits terminally ill patients to access investigational drugs post-Phase I.
  • European Union: The EMA supports compassionate use programs implemented nationally.
  • United Kingdom: The Early Access to Medicines Scheme (EAMS) allows pre-approval access.
  • Australia: The TGA’s Special Access Scheme enables case-by-case use of unapproved therapies.
  • Canada: Health Canada’s Special Access Program permits similar one-off access.
  • Philippines: The FDA’s Compassionate Special Permit allows access to unregistered drugs.

These frameworks reflect a growing global movement toward patient-directed, flexible access to therapies—while revealing major ethical and clinical concerns.

Ethical and Regulatory Implications

Critics of Montana’s approach note that Phase I trials are too limited to assess therapeutic benefit or longer-term safety. Despite licensing and informed consent safeguards, concerns persist around exploitation, false hope, and patient harm—echoing tragedies like the thalidomide crisis, which shaped modern regulatory norms (Bateman-House, as cited in Hamzelou, 2025).

This intersects directly with GMDP Academy’s mission: to prepare professionals to ethically manage innovation in a rapidly evolving biopharma landscape. As outlined in the Grand Challenges in Pharmaceutical Medicine series, the future of medicines development must balance accessibility, patient safety, and evidence-based practice.

A Global Conversation on Access and Innovation

Venture capitalist Niklas Anzinger, founder of Infinita in Roatán, Honduras, describes his vision for experimental therapies as creating a “Los Alamos for Longevity.” This metaphor invokes the high-stakes innovation environment of the U.S. nuclear project, reimagined for anti-aging and regenerative medicine (Hamzelou, 2025). He, along with longevity researcher Todd White, helped draft Montana’s new legislation to position the state as a medical tourism hub for U.S. citizens seeking fast-track access to experimental treatments.

This vision aligns with other regulatory experiments worldwide. As these models proliferate, they force a broader question: how should medicines developers ethically and scientifically respond?

Conclusion

The Montana legislation represents a pivot in access to experimental medicine—moving beyond terminal illness exceptions toward broader consumer choice. For the global GMDP Academy community, this is a critical moment for professional reflection.

Trained to uphold high ethical standards while promoting innovation, GMDP Academy learners are uniquely positioned to shape this future—one that embraces both medical progress and rigorous patient protection.

References

Hamzelou, J. (2025, May 14). The first US hub for experimental medical treatments is coming. MIT Technology Review. https://www.technologyreview.com/2025/05/14/1116428/first-us-hub-for-experimental-medical-treatments/

Silva, H., Stonier, P., Chopra, P., Coots, J., Criscuolo, D., Guptha, S., … & Vandenbroucke, P. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King’s College, London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036:contentReference[oaicite:2]{index=2}

Silva, H., Kerpel-Fronius, S., Stonier, P. D., & Dubois, D. J. (Eds.). (2021). Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers Media SA. https://doi.org/10.3389/978-2-88966-986-8:contentReference[oaicite:3]{index=3}

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred